Home » Alumni » Researchers’ sensor integrates inflammatory bowel disease detection into colonoscopy procedure

Researchers’ sensor integrates inflammatory bowel disease detection into colonoscopy procedure

 

The sensor detects molecular markers of IBD using a minimally-invasive endoscope that can be easily integrated into a routine colonoscopy exam. Credit: Vanderbilt University

Vanderbilt researchers have developed the first sensor capable of objectively identifying inflammatory bowel disease (IBD) and distinguishing between its two subtypes. The device represents a substantial achievement toward a more personalized approach to diagnosing and treating IBD, a chronic inflammation of the gastrointestinal tract affecting more than 1 million Americans.

Current diagnostic and treatment procedures for IBD are inexact and rely largely on trial-and-error. In The Optical Society’s journal Biomedical Optics Express, researchers report on a pilot study of a custom-developed endoscope that uses the chemical-fingerprinting technique Raman spectroscopy to detect molecular markers of IBD in the colon, as featured Jan. 4, 2017 by Phys.Org.

The sensor is designed as a minimally-invasive probe that can be easily integrated into a routine colonoscopy exam. After further refining, the researchers say doctors could use the device to help diagnose IBD and evaluate a patient’s response to treatment.

Anita Mahadevan-Jansen

“With current methods, ultimately the diagnosis is dependent on how the patient responds to therapy over time, and you often don’t know the diagnosis until it’s been a few years,” said senior author of the paper, Anita Mahadevan-Jansen, Orrin H. Ingram Professor of Biomedical Engineering and director of the Biophotonics Center at Vanderbilt University. “That’s why we decided to use a light-based method to probe the biochemistry of what’s going on in the colon. Our goal is to use Raman spectroscopy to look at the actual inflammatory signals.”

Doctors currently use a combination of clinical, radiologic and pathological methods to diagnose a patient’s IBD subtype and guide treatment decisions, but these methods detect symptoms, rather than the underlying source of disease, and the process has lacked an objective gold standard. As a result, up to 15 percent of patients are diagnosed with indeterminate colitis, meaning the subtype is unknown, and an additional 5 to 14 percent have their IBD reclassified based on how they respond to treatment.

Previous research conducted in tissue samples from people with IBD showed that UC and Crohn’s disease have different molecular signatures. The new probe detects these signatures in order to glean information about not only disease subtype, but also the current degree of inflammation and even early indicators of IBD that occur before observable changes in the intestinal tissue.

“Most people go through baseline colonoscopy as part of routine care, and you could imagine using this to get a baseline Raman signal for each person,” said Mahadevan-Jansen. “If someone presents with IBD symptoms later on, you can use our system again to determine if it’s more likely to be UC or Crohn’s. Then once they are being treated, you have an objective measure to track their response because you can use the device to actually quantify mild, moderate or severe inflammation.”

The researchers are now focused on refining a set of algorithms that help doctors interpret test results for a given patient. To improve the test’s specificity, the team is analyzing data from an expanded cohort of patients to discern how factors such as gender, diet, demographics and treatment regimen influence the Raman signature. Ultimately, they envision a system that combines key information about the patient with Raman spectra to deliver, in a matter of seconds, tailored results that can inform a diagnosis or help track a patient’s response to treatment.

“It’s a unique way of thinking about personalized medicine that takes into account all sorts of information – beyond just the genome – including demographics and many other factors that make a person unique,” said Mahadevan-Jansen. “Our lab has really pushed to find ways to apply optical technology to support this kind of personalized medicine.”

Read more at: http://phys.org/news/2017-01-sensor-inflammatory-bowel-disease-colonoscopy.html#jCp


Posted on Thursday, January 5, 2017 in Alumni, Biomedical Engineering, Home Features, Media, News, Research.

Tags: , , , , ,



Leave a Reply

News